Company profile
Samsung Bioepis
Privately held: no public share price
Assets
(3 total)
3Total Assets
3Approved
0Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Approved | TNF-alpha | Inflammatory Bowel DiseasePsoriatic Arthritis Ulcerative Colitis, Crohn's Disease | |
| Approved | TNF-alpha | Inflammatory Bowel Disease Ulcerative Colitis, Crohn's Disease | |
| Approved | IL-23 p19 · IL-12 p40 | Inflammatory Bowel DiseasePsoriatic Arthritis Ulcerative Colitis, Crohn's Disease |
Upcoming events
Research
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.